Incyte Names New Member to Its Board of Directors
October 04 2022 - 8:00AM
Business Wire
Incyte (Nasdaq:INCY) announces the appointment of Susanne
Schaffert, Ph.D., as a new member of its Board of Directors.
“On behalf of the Incyte Board of Directors, I am happy to
welcome Susanne. Her extensive commercial, development and industry
experience will greatly complement our Board and we look forward to
Susanne’s contributions to our continued growth and future
success,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
“I am very excited for the opportunity to join the Incyte Board
of Directors and helping the organization in its commitment to
leading scientific innovation and developing new medicines for
patients in need. I look forward to being part of this dynamic
Company,” said Dr. Schaffert.
For 26 years, Dr. Schaffert served in various global, regional
and national roles of increasing responsibilities at Novartis AG
including, most recently, as President of Novartis Oncology where
she oversaw a very broad portfolio in Solid Tumors and Hematology.
Prior to that role, Dr. Schaffert served from 2018 to 2019 as
President and Chair of Accelerated Advanced Applications, launching
the first radio-ligand therapy in Neuroendocrine tumors, and from
2012 to 2018 as General Manager Region Europe, Novartis Oncology.
Prior to those positions, Dr. Schaffert was Global Head of Investor
Relations, Global Franchise Head for Immunology and Transplantation
and held a series of positions in sales and marketing from the time
she joined Novartis Germany in 1995. Dr. Schaffert is also a member
of the board of directors of Rubius Therapeutics, Inc.
About Incyte Incyte is a Wilmington, Delaware-based,
global biopharmaceutical company focused on finding solutions for
serious unmet medical needs through the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit Incyte.com and follow
@Incyte.
Forward-Looking Statements Except for the historical
information set forth herein, the matters set forth in this press
release contain predictions, estimates and other forward-looking
statements. These forward-looking statements are based on the
Company’s current expectations and subject to risks and
uncertainties that may cause actual results to differ materially,
including risks related to market competition, the results of and
risks associated with research and development, risks and
uncertainties associated with sales, marketing and distribution
requirements, and other risks detailed from time to time in the
Company’s reports filed with the Securities and Exchange
Commission, including its annual report and its quarterly report on
Form 10-Q for the quarter ended June 30, 2022. Incyte disclaims any
intent or obligation to update these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221004005151/en/
Media Catalina Loveman +1 302 498 6171
cloveman@incyte.com
Investors Christine Chiou +1 302 274-4773
cchiou@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024